JavaScript is NOT enabled !

Please enable JavaScript.

Article

PubMed

This record comes from PubMed

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

Szturz, Petr
Author Szturz, Petr Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. petr.szturz@fnbrno.cz Department of Internal Medicine, Hematology and Oncology, School of Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic. petr.szturz@fnbrno.cz
Specenier, Pol
Author Specenier, Pol Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Van Laer, Carl
Author Van Laer, Carl Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium
Van Den Weyngaert, Danielle
Author Van Den Weyngaert, Danielle Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Radiotherapy, University Radiotherapy Antwerp, Antwerp, Belgium
Corthouts, Bob
Author Corthouts, Bob Department of Radiology, Antwerp University Hospital, Edegem, Belgium
Carp, Laurens
Author Carp, Laurens Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium
Van Marck, Eric
Author Van Marck, Eric Department of Pathology, Antwerp University Hospital, Edegem, Belgium
Vanderveken, Olivier
Author Vanderveken, Olivier Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium
Vermorken, Jan B
Author Vermorken, Jan B Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

European archives of oto-rhino-laryngology. 2016 Jun ; 273 (6) : 1629-36. [epub] 20150605

Eur Arch Otorhinolaryngol
ISSN 1434-4726 | 0937-4477
Source

Language English Country Germany Media print-electronic

Document type Case Reports, Journal Article

Persistent link https://www.medvik.cz/link/pmid26044403

PubMed 26044403
DOI 10.1007/s00405-015-3673-y
PII: 10.1007/s00405-015-3673-y
Knihovny.cz E-resources

Keywords
Epidermal growth factor receptor inhibitor, Positron emission tomography, Targeted therapy, Taxanes, Tonsil cancer,
MeSH
Time Factors MeSH
Cetuximab administration & dosage MeSH
Cisplatin administration & dosage MeSH
Docetaxel MeSH
Fluorouracil administration & dosage MeSH
Remission Induction MeSH
Quality of Life MeSH
Middle Aged MeSH
Humans MeSH
Neoplasm Recurrence, Local diagnostic imaging drug therapy MeSH
Head and Neck Neoplasms diagnostic imaging drug therapy MeSH
Positron Emission Tomography Computed Tomography MeSH
Disease-Free Survival MeSH
Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
Carcinoma, Squamous Cell diagnostic imaging drug therapy MeSH
Taxoids administration & dosage MeSH
Tonsillar Neoplasms diagnostic imaging drug therapy MeSH
Treatment Outcome MeSH
Check Tag
Middle Aged MeSH
Humans MeSH
Male MeSH
Publication type
Journal Article MeSH
Case Reports MeSH
Names of Substances
Cetuximab MeSH
Cisplatin MeSH
Docetaxel MeSH
Fluorouracil MeSH
Taxoids MeSH

BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS: In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS: Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.

Department of Internal Medicine Hematology and Oncology School of Medicine University Hospital Brno and Masaryk University Brno Czech Republic

Department of Medical Oncology Antwerp University Hospital Wilrijkstraat 10 2650 Edegem Belgium

Department of Nuclear Medicine Antwerp University Hospital Edegem Belgium

Department of Otorhinolaryngology and Head and Neck Surgery Antwerp University Hospital Edegem Belgium

Department of Pathology Antwerp University Hospital Edegem Belgium

Department of Radiology Antwerp University Hospital Edegem Belgium

Department of Radiotherapy University Radiotherapy Antwerp Antwerp Belgium

Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

See more in PubMed

Clin Cancer Res. 2006 Sep 1;12(17):5064-73 PubMed

Cancer. 2001 Apr 1;91(7):1316-23 PubMed

PLoS One. 2014 Aug 08;9(8):e103918 PubMed